RT Journal Article
SR Electronic
T1 Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of lung cancer
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P4213
VO 40
IS Suppl 56
A1 Shih-Lung Cheng
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P4213.abstract
AB We recently found that the expression of placenta growth factor (PlGF) in lung cancer specimens is correlated with the progression and prognosis. In this study, serum samples were obtained from 72 patients with lung cancer and from 30 normal controls. Serum PlGF levels were determined by enzyme-linked immunosorbent assay (ELISA). The mean serum PlGF levels were significantly higher in lung cancer patients than in normal controls (19.1 ± 10.7 vs. 10.1 ± 4.5, P < 0.001). Serum PlGF levels dropped to near the normal control levels after surgical cancer removal. Higher pre-surgery serum PlGF levels were significantly associated with larger tumor size (P = 0.015), positive lymph node metastasis (P = 0.001), more advanced clinical stages (P = 0.002), and loco-regional recurrence (P = 0.037). The serum PlGF level was identified as an independent unfavorable prognosis factor by multivariate Cox regression analyses (P = 0.014). Kaplan-Meier curve showed that lung cancer patients with a higher serum PlGF level had a significantly poorer cumulative recurrence-free survival than those with a lower serum PlGF level (log-rank test, P = 0.009). When we used the serum PlGF level of 19.1 pg/ml as a cutoff point, the sensitivity, specificity, and positive predictive value for tumor recurrence was 80%, 56% and 78%, respectively. We conclude that the serum PlGF level may be a valuable biomarker for prediction of therapeutic effect, progression, recurrence and prognosis of lung cancer.